Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study-Reference-Cited by-同舟云学术

Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study

Published:2019-12 Issue:12 Volume:20 Page:1670-1680
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Hui Rina,Özgüroğlu Mustafa,Villegas Augusto,Daniel Davey,Vicente David,Murakami Shuji,Yokoi Takashi,Chiappori Alberto,Lee Ki Hyeong,de Wit Maike,Cho Byoung Chul,Gray Jhanelle E,Rydén Anna,Viviers Louis,Poole Lynne,Zhang Yiduo,Dennis Phillip A,Antonia Scott J

Publisher

Elsevier BV

Subject

Oncology

Reference29 articles.

1. Therapeutic management options for stage III non-small cell lung cancer;Yoon;World J Clin Oncol,2017

2. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015;Lancet,2016

3. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer;Aupérin;J Clin Oncol,2010

4. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Postmus;Ann Oncol,2017

5. Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small-cell lung cancer: KCSG-LU05–04;Ahn;J Clin Oncol,2015

Cited by 120 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Abscopal effect: from a rare phenomenon to a new frontier in cancer therapy;Biomarker Research;2024-09-04

2. PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer;Future Oncology;2024-07-18

3. Durvalumab supplementation for non-small-cell lung cancer: a meta-analysis study;Journal of Cardiothoracic Surgery;2024-07-04

4. Patient-reported outcomes after personalised dose-escalation for stage II-III non-small-cell lung cancer patients: Results from the randomised ARTFORCE PET-Boost trial;Radiotherapy and Oncology;2024-07

5. Immunotherapy in non-small cell lung cancer: current status, advances and challenges;Minerva Respiratory Medicine;2024-07